產(chǎn)品展示
艾美捷 LKT Labs 阿達(dá)格拉西布解決方案
點(diǎn)擊次數(shù):0發(fā)布時(shí)間:2023/5/23 16:45:10
更新日期:2023/5/23 16:45:10
所 在 地:中國(guó)大陸
產(chǎn)品型號(hào):
優(yōu)質(zhì)供應(yīng)
詳細(xì)內(nèi)容
艾美捷 LKT Labs 阿達(dá)格拉西布基礎(chǔ)信息:
編號(hào):A121008
cas:2326521-71-3
純度:≥99%
公式:C32H35ClFN7O2
配方重量:604.13
IUPAC名稱:2-[(2S)-4-[7-(8-氯萘-1-基)-2-[[(2S)-1-甲基吡咯烷-2-基]甲氧基]-6,8-二氫-5H-吡啶并[3,4-d]嘧啶-4-基]-1-(2-氟丙基-2-烯;┻哙-2-基]乙腈
同義詞:MRTX-849
外觀:白色粉末
阿達(dá)格拉西布文獻(xiàn)參考:
Zhang Y, Li C, Xia C, et al. Adagrasib, a KRAS G12c inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Commun Signal. 2022 Sep 14;20(1):142. PMID: 36104708
Sabari J, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12c-mutant non-small cell lung cancer. Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. PMID: 35404402
Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12c inhibitors, sotorasib and adagrasib, and overcoming strategies: insights form in vitro experiments. J Thorac Oncol. 2021 Aug;16(8):1321-1332. PMID: 33971321
來(lái)源:https://www.amyjet.com/products/LKT-A121008-1mg.shtml